Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just a matter of time.
Just another alias, eh?
Conflicts of interest are extremely important considerations, especially when it comes to clinical trials — that’s just reality.
So, you don’t believe that the SAB plays a role in advising the company on scientific and regulatory matters related to the trials?
Interesting.
Vator, completely agree.
One other point to make is the importance of having LL on the SAB given her experience and intimate knowledge of the trial for L, especially as it relates to advising on the pending combo trials. Nobody else other than Ashkan has that specific knowledge and experience.
Also confirms in my opinion that the discussion over the combo trials either is at least close to final, or has at least making substantial progress.
I wonder where the break is whereby there is no longer any concern over conflicts of interest — could it relate to submission of the application?
Gary, that’s exactly right. MMs and traders will often go both long and short in a stock. A fairly common practice. So the question is how many of the short shares are open positions without corresponding long shares to cover? It’s called a covered straddle to be both long and short in a stock in order to play the spread.
The naked short narrative is old and unproven.
Finra, profits over ?
We shall see, Tutanota Man.
I really don’t care what you do.
But my lawyer does.
I stickied Dstock’s post.
Do you want me to remove his post?
If you want me to remove these posts, please just let me know. Happy to help!
So you’re not defending a company that was blinding patients and violating the law?Meaning, even a company that engaged in illegal and harmful activities is beyond criticism and you’re okay with that…is that what you’re saying?
You see, the same individual posting under various aliases.
Next time you write a Reddit article, do some research.
U.S. District Judge Ursula Ungaro of the Southern District of Florida granted the government’s motion for summary judgment against US Stem Cell Clinic LLC, of Weston, Florida, and US Stem Cell Inc., of Sunrise, Florida, and their Chief Scientific Officer Kristin Comella, Ph.D. The court held that the defendants in that case adulterated and misbranded a stem cell drug product made from a patient’s adipose tissue.
I know it’s you.
Read this about the company you are advocating and defending.
https://www.fda.gov/news-events/press-announcements/federal-court-issues-decision-holding-us-stem-cell-clinics-and-owner-adulterated-and-misbranded-stem
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/us-stem-cell-clinic-llc-524470-08242017
Haha!
Do you think you can have your Reddit “article” accepted for publication by a legitimate platform?
Reads like a third grader wrote it.
I’m still here!
There’s not much to say at this point, now that we have some visibility on timing.
We shall see.
I really, really hope so!
Bottom line for now is that investors have some relief that the arrow is moving in the right direction.
Nobody could say that yesterday.
Really?
I’m literally reading the press release that states 30 to 45 days for submission. And another 150 day MHRA review process. That’s in their own press release — what’s there to debate?
150+30=180
180/30= 6 months
Agree with this entirely.
The lack of any guidance was strangling the stock price. We’re still a half year from approval, but investors at least know where things stand.
Sounds good to me.
In due time my friend.
My first buys were between $3 and $4. My recollection is that when LL said that everybody is living longer, that triggered the self off — I actually had no real understanding at the time as to the reason for the sell off. And actually saw her comment as a positive signal that Vax was working on patients even in the cross over.
But I learned a lot about pseudo progression and the cross over the next year or so. And had to brush up on my statistics as well!
Conspiracy theories are intoxicating. So I understand that no matter what someone says to contradict the conspiracy, some posters will just keep hanging on.
That’s a fair point. Since I have a little more time today, I’ll address your concern.
The way I became involved with USRM is I knew a couple of investors that were financially hurt by this company. A prominent poster on this very message board was actually a pumper of that stock. He in fact knows the CEO. I know his actual name. But of course will not share the name or alias of that individual.
This was a company that was effectively a scam that sold unapproved and unregulated adipose stem cell treatments that harmed people, and led to premature blindness in several individuals. Financially, the company was highly questionable and the last I checked is a gray sheet trading at 0.0002 per share.
The company was bringing lawsuits against anyone who was critical of their financial and business practices. But as you see from the below attachments, that’s what I was advocating against using my brand of humor. USRM has been party to a number of lawsuits, including at least a couple that are on-going.
I may have saved some investors from losing money and perhaps some people from being hurt and blinded.
Anyone here want to defend a financially questionable company that was selling unregulated and unapproved stem cell treatments that led several individuals to become blind..
be my guest!
https://www.fda.gov/news-events/press-announcements/federal-court-issues-decision-holding-us-stem-cell-clinics-and-owner-adulterated-and-misbranded-stem#:~:text=The%20U.S.%20Department%20of%20Justice%2C%20on%20FDA
https://ipscell.com/2023/05/us-stem-cell-says-it-10-others-face-malpractice-suits/
https://www.washingtonpost.com/national/health-science/this-clinics-experimental-stem-cell-treatment-blinded-patients-four-years-later-the-government-is-still-trying-to-shut-it-down/2019/04/03/432d6d04-ff2f-11e8-83c0-b06139e540e5_story.html
MIAMI — In the summer of 2015, ophthalmologist Thomas Albini examined a patient who had suddenly lost vision in both eyes. The woman, 78, had macular degeneration and had visited a Miami clinic offering a new treatment: injections of stem cells made from fat in her belly.
Instead of getting better, the woman’s vision deteriorated significantly. Peering into her eyes, Albini said, he saw clumps of blood floating inside.
The next day, a second patient appeared in Albini’s emergency room at the University of Miami complaining of blindness and searing pain after receiving eye injections from the same company,U.S. Stem Cell. Albini reported the cases to the U.S. Food and Drug Administration, urging an investigation.
Now, the FDA is suing to stop the company’s treatments in federal court in Fort Lauderdale, Fla., in one of the government’s most aggressive actions against the burgeoning stem cell business. With the judge expected to rule any day on the government’s charge that U.S. Stem Cell is “openly violating the law and endangering patients,” legal experts say the case could constrain a lucrative industry accused by doctors, lawyers and federal officials of harming dozens of people.
Hank, I’ve already posted my agreement with everything you list. If you go through my posts, they align with each of your points. Easy peezy.
That’s a fair point. Since I have a little more time today, I’ll address your concern.
The way I became involved with USRM is I knew a couple of investors that were financially hurt by this company. A prominent poster on this very message board was actually a pumper of that stock that led to that couple getting investing in that company’s stock. He in fact knows the CEO. I know his actual name. But of course will not share the name or alias of that individual.
This was a company that was effectively a scam that sold unapproved and unregulated adipose stem cell treatments that harmed people, and led to premature blindness in several individuals. Financially the company was highly questionable and the last I checked is a gray sheet trading at 0.0002 per share. The company was bringing lawsuits against anyone that was critical of their financial and business practices. But as you see from the below attachments, what I was advocating against. USRM has been party to a number of lawsuits, including at least a couple that are on going.
I may have saved some investors from losing money and perhaps some people from being hurt and blinded.
https://www.fda.gov/news-events/press-announcements/federal-court-issues-decision-holding-us-stem-cell-clinics-and-owner-adulterated-and-misbranded-stem#:~:text=The%20U.S.%20Department%20of%20Justice%2C%20on%20FDA
https://ipscell.com/2023/05/us-stem-cell-says-it-10-others-face-malpractice-suits/
https://www.washingtonpost.com/national/health-science/this-clinics-experimental-stem-cell-treatment-blinded-patients-four-years-later-the-government-is-still-trying-to-shut-it-down/2019/04/03/432d6d04-ff2f-11e8-83c0-b06139e540e5_story.html
MIAMI — In the summer of 2015, ophthalmologist Thomas Albini examined a patient who had suddenly lost vision in both eyes. The woman, 78, had macular degeneration and had visited a Miami clinic offering a new treatment: injections of stem cells made from fat in her belly.
Instead of getting better, the woman’s vision deteriorated significantly. Peering into her eyes, Albini said, he saw clumps of blood floating inside.
[The next day, a second patient appeared in Albini’s emergency room at the University of Miami complaining of blindness and searing pain after receiving eye injections from the same company,U.S. Stem Cell. Albini reported the cases to the U.S. Food and Drug Administration, urging an investigation.
Now, the FDA is suing to stop the company’s treatments in federal court in Fort Lauderdale, Fla., in one of the government’s most aggressive actions against the burgeoning stem cell business. With the judge expected to rule any day on the government’s charge that U.S. Stem Cell is “openly violating the law and endangering patients,” legal experts say the case could constrain a lucrative industry accused by doctors, lawyers and federal officials of harming dozens of people.
I think being poor is the only thing that keeps me alive.
I’m still a relatively large shareholder.
Crash likely knows that and how many shares I own.
It is a lot of work preparing for litigation, so it may take me some time. But in the process as I was going through my files, I found this email I sent to Les on February 29, 2016. Woke up (it was a leap year, so dated February 29, 2016), so quickly drafted an email to Les before I had my first cup of coffee and headed out the door.
The stock price opened on Nasdaq that day at above $2.00 and closed at $1.84. I had owned the stock for less than a year — maybe just a few months — at that point; my first purchases were between $3 and $4 per share. The stock was traded on Nasdaq and the outstanding share count was just north of 100 million shares. Wish I had known then what I know now. Could have fixed a few typos as well.
Actually, I would like to see better governance and management, which everyone would benefit from.
I’ll share a corresponding with Les from years ago. If I have time to dig it out.
Here’s the interesting thing: I’m actually a large shareholder and the company and its social media consultants know it.
But in due time.
Look at the balance sheet, and tell me where the capital came from?
Since NWBO (and by extension shareholders) provided the startup capital by way of whatever contracts were signed, why isn’t Advent a subsidiary of NWBO? And by having the same person in substantial control of both entities, why isn’t that a significant conflict of interest?
If you provide the capital in whatever form, you should own the asset.
Right?
Aesop, What I find remarkable with Advent’s balance sheet is that contributed capital is only ONE English Pound (£1) and all its equity is earnings and there are ore no other sources of capital. Let’s just say that’s very unusual.
Also, Aesop, if you have the names of NWBO’s social media consultants, I appreciate if you forward that to me. Thanks!
Oh, situational ethics…but mine does too. Just a bit.
You’re still welcome to my food truck.
I don’t care what DStock says about you behind your back.
Here’s the thing Dr., I really don’t care if he is or isn’t. But he does add value in terms of his knowledge of the sector. Anyone should be able to take someone’s comments and decide what they find of value or not. And not make a big deal over what they don’t agree with.
There’s something philosophical in that approach.
You seem to have an inconsistent point of view?
That’s an interesting point Dr. Bala. You really don’t need to be in agreement with management to be an investor — couldn’t have said that better myself. And I would take it one step further — you don’t even have to be an investor to be right. That’s actually irrelevant to someone’s understanding of this company and biotech in general. Mav has been remarkably right in terms of his timelines and his understanding of this sector.
It depends on the viewpoint. You stick to yours and I will, to mine.Don't need to support the management to be a true investor. It doesn't ultimately matter what my opinion is about your strategy